Monkey acne was introduced to the Mainland; the unmanned nucleic acid meter measured 10,000 people a day; the cadre leaked the epidemic was filed

Author:Kenji Bureau Time:2022.09.18

On September 17, Guizhou's newly added local infected infected people suddenly increased to 662 cases, setting a new high since the epidemic. Only 31 high -risk areas in Guiyang City alone. During this week, Guizhou Province once again urgently added 80 million yuan to purchase epidemic prevention supplies.

In order to make nucleic acid more convenient, the first domestic nucleic acid detection platform with high portable portability and fully realized automated operation was approved for listing. The product covers an area of less than 0.4m², and the equipment weighs only 45kg. It can be restricted by the personnel. Help complete nucleic acid detection.

During this week, a case of diagnosed monkey acne discovered by Chongqing has aroused the attention of all sectors of society. This is the first case of monkey acne in the Mainland. Monkey acne is already a public health incident identified by the WHO. Domestic experts said that the prevention and control of China is relatively strict and does not need to vaccinate the vaccine to prevent monkey acne.

In terms of new drugs, Skysona, the second gene therapy of Blue Bird, was accelerated and approved by FDA. The unit price of this product is 3 million US dollars, becoming the most expensive drug in the world.

More information, sort out as follows:

Heavy policy

1.2022 Medical Insurance passed the list of drugs to be released in the form of censorship

On September 17, the State Medical Insurance Bureau issued the "National Medical Security Bureau on the announcement of the announcement of national basic medical insurance, work injury insurance and maternity insurance drug catalogs in 2022". A total of 343 drugs passed the form of review. The new oral special effects medicine Azfding, the U.S. -Gold Vae -oral solid membrane used to treat Aldzheimer's disease, etc. are all among them.

After the form review, the relevant drugs will also be included in the national medical insurance directory after the expert review and negotiation bidding.

2. Guizhou has invested 130 million yuan in emergency funds to prevent epidemic prevention

On September 13, Guizhou Province released a new news that with the consent of the provincial government, the Guizhou Provincial Department of Finance urgently added 80 million yuan to prevent and control pharmaceutical materials reserve emergency procurement for spare money, mainly used to purchase new crown antigen reagents.

Prior to September 8th, the Guizhou Provincial Department of Finance had urgently added 50 million funds for epidemic prevention and procurement, focusing on purchasing urgently needed nucleic acid testing agents, protective clothing, isolation clothes, goggles and other medical materials.

Recently, the outbreak of the outbreak of Guizhou Province. Previously, due to the collapse of the nucleic acid detection system, Guizhou Big Data Company also issued an apology statement on the cloud. As of 24:00 on September 17, there were 94 confirmed cases in Guizhou Province and 2030 asymptomatic infections.

3. Chengdu: Four cadres leaked the epidemic information information was notified

On September 18, the Chengdu Discipline Inspection Commission issued a notification on three typical cases of violations of work discipline.

Li Yue, member of the Standing Committee of the Dujiangyan Municipal Party Committee and Minister of Propaganda, Liu Yongmei, Secretary of the Party Committee of Qingyang District Health and Health Commission, Liu Wei, Secretary of the Party Committee of Dongsheng Street Party Working Committee of Shuangliu District, Li Dewen, Secretary of the Party Committee of Yixin Street. Take a picture with your mobile phone and send the photos to private WeChat via WeChat, causing information leakage, causing serious adverse effects, and it has been filed for review.

Industry affairs

1. Small drone nucleic acid detector is approved to be listed

On September 12, Zhijiang Biological announced that the company's self -developed automatic nucleic acid detection system obtained the three types of medical device registration certificates of the country. This is currently the smallest and most automated nucleic acid detection equipment in China, which is convenient for moving. It is suitable for various laboratories, as well as places with relatively limited space environments such as mobile vehicles.

It is understood that the product covers an area of less than 0.4m², and the equipment weighs only 45kg. It can automatically complete the full process of nucleic acid detection in the absence of unmanned operation to effectively alleviate the problem of insufficient detection personnel.

According to Pengbai News, the product listed this time is called "Xiao Qing Geng", which can complete the test of 960 people samples in 2 hours. Earlier, the "Qing Geng No. 1" of the nucleic acid detection machine "Qing Geng No. 1", which has been listed in Zhijiang Bio, required manual intervention 4 times in 24 hours, which can complete 90,000 nucleic acid detection in one day.

Zhijiang Bio is a listed company of the main molecular diagnostic reagent and instrument and equipment. The total revenue from 2017-2019 was 193 million yuan, 224 million yuan, and 259 million yuan. In 2021, the revenue soared to 2.019 billion yuan.

2. Monkey -acne cases have been introduced in China

On September 16th, according to CCTV News, a case of diagnosis in Chongqing's diagnosis was diagnosed by overseas acne. The new crown detection was negative. The case of this case was isolated in Chongqing and has no social activities. After conducting the tightly tested tunnel of the tight contact with it, all the results were negative.

At present, there are already monkey acne nucleic acid detection products. Zhijiang Biology, Wanfu Biology, Daannin, and Shengxiang Bio can be produced.

Wu Zunyou, chief scientist of the China Centers for Disease Control and Prevention, pointed out that the spread of monkey acne is more complicated. In terms of prevention, it should be a good prevention of contact with people's skin. Most people with acne infection will recover within a few weeks, and there is no need to vaccinate vaccine to prevent monkey acne.

Earlier in July, the WHO officer Tan Detai announced that the epidemic of the monkey acne was listed as an internationally concerned public health incident. The last event at the same level was the new crown epidemic. As of now, the case of poxing has emerged in more than 90 countries, with nearly 32,000 related cases, of which the United States has reported more than 21,000 diseases, and two cases of death have occurred. In August, the Biden government announced that monkey acne was an emergency of public health.

3. Grand Shi Bioskin's fixed increase of 4 billion plans was approved

On September 15, Junshi Biological announced that the company was approved by the Shanghai Stock Exchange to add shares to specific objects.

According to the previous fundraising instructions, Junshi's fundraising amount was 3.969 billion yuan, of which 3.617 billion yuan was used for innovative drug research and development projects, and 298 million yuan was used for Shanghai Junshi Biotechnology Headquarters and R & D base projects. The additional price is around 56 yuan.

The fixed increase plan of the Junshi Bio was launched in March this year. At that time, due to its rapid research and development progress in its new crown special drug VV116, the stock price of Junshi Bio was once rushed to 130 yuan. However, with the real creature, Azf will be listed as the new crown oral medication, the popularity of VV116 has declined. In the first half of 2022, the net loss of Junshi Bio was nearly 1 billion yuan, and the stock price had dropped to less than 50 yuan.

New drug inventory

1. Eli Loss weight loss pills are approved clinically in China

On September 15th, according to the official website of CED, the Tirzepatide injection of Lilly was approved by the clinic for drug intervention treatment for adult overweight and obese people, reducing the risk of its main cardiovascular events, reducing the risk of type 2 diabetes and improving the kidneys ending.

Tirzepatide is a long-acting GLP-1R/GIPR dual agonist that treats type 2 diabetes. It was listed in the United States in May 2022. In September, the listing of the indications was accepted by the China Drug Administration.

2. 3 million US dollars a needle, blue bird biological gene therapy drugs are listed

On September 16, the Blue Bird Biological Announcement stated that the company's gene therapy product Skysona was accelerated to the market by FDA to slow down the progress of children's neurological dysfunction of children's neurological dysfunction in early 4-17 years old.

Bluebird biological pricing The cost of this medicine in the United States is $ 3 million. This is the second gene therapy approved to be listed. The previous one was the treatment of children's Mediterranean anemia Beti-Cel, which was priced at $ 2.8 million once. Both medicines are more expensive than the Nuohua Sky Valentine of $ 2.1 million.

CALD is a kind of disease that is mainly in men aged 5-12. In the early stage, it manifested as not concentration, memory loss, difficulty in learning, unstable gait, abnormal behavior, etc., and may develop to paralysis, blindness or deafness, etc. symptom. According to the survey, nearly half of the patients will die within 5 years of symptoms.

Skysona, which is 3 million US dollars, can fundamentally relieve the condition at one time. However, the FDA also warned that the use of this drug may have a malignant tumor with a blood system.

3. Pfizer: Start mRNA flu vaccine phase III clinical

On September 14, Pfizer claimed that the four -price modification RNA flu vaccine in the research had completed the first batch of patients' administration and included 25,000 American adults.

This is Pfizer's first MRNA flu vaccine to enter the stage III. According to previously disclosed phase II clinical results: After 7 days of injection of adults over 65 years of age, the immune response caused by the mRNA flu vaccine was much higher than that of ordinary influenza vaccines.